1. Home
  2. MIRM vs SKYH Comparison

MIRM vs SKYH Comparison

Compare MIRM & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • SKYH
  • Stock Information
  • Founded
  • MIRM 2018
  • SKYH 2017
  • Country
  • MIRM United States
  • SKYH United States
  • Employees
  • MIRM N/A
  • SKYH N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • SKYH Military/Government/Technical
  • Sector
  • MIRM Health Care
  • SKYH Industrials
  • Exchange
  • MIRM Nasdaq
  • SKYH Nasdaq
  • Market Cap
  • MIRM 3.3B
  • SKYH 341.8M
  • IPO Year
  • MIRM 2019
  • SKYH N/A
  • Fundamental
  • Price
  • MIRM $74.31
  • SKYH $10.07
  • Analyst Decision
  • MIRM Strong Buy
  • SKYH Strong Buy
  • Analyst Count
  • MIRM 10
  • SKYH 3
  • Target Price
  • MIRM $74.20
  • SKYH $14.83
  • AVG Volume (30 Days)
  • MIRM 752.1K
  • SKYH 86.7K
  • Earning Date
  • MIRM 11-11-2025
  • SKYH 11-11-2025
  • Dividend Yield
  • MIRM N/A
  • SKYH N/A
  • EPS Growth
  • MIRM N/A
  • SKYH N/A
  • EPS
  • MIRM N/A
  • SKYH N/A
  • Revenue
  • MIRM $429,161,000.00
  • SKYH $20,919,000.00
  • Revenue This Year
  • MIRM $53.08
  • SKYH $124.39
  • Revenue Next Year
  • MIRM $20.45
  • SKYH $83.05
  • P/E Ratio
  • MIRM N/A
  • SKYH N/A
  • Revenue Growth
  • MIRM 62.33
  • SKYH 94.38
  • 52 Week Low
  • MIRM $36.86
  • SKYH $9.28
  • 52 Week High
  • MIRM $78.10
  • SKYH $14.52
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 63.07
  • SKYH 44.36
  • Support Level
  • MIRM $73.70
  • SKYH $9.91
  • Resistance Level
  • MIRM $77.96
  • SKYH $10.19
  • Average True Range (ATR)
  • MIRM 2.48
  • SKYH 0.26
  • MACD
  • MIRM -0.54
  • SKYH -0.06
  • Stochastic Oscillator
  • MIRM 48.19
  • SKYH 19.61

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About SKYH Sky Harbour Group Corporation

Sky Harbour Group Corp is an aviation infrastructure company building a nationwide network of Home-based solutions for business aircraft. The company develops, leases, and manages business aviation hangars across the United States based on its proprietary targeting and acquisition model, targeting airfields with hangar supply and demand imbalances in the markets. Its hangar campuses feature exclusive private hangars and a full suite of dedicated services specifically designed for home-based aircraft.

Share on Social Networks: